Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bayer (GB:0P6S)
LSE:0P6S
Holding GB:0P6S?
Track your performance easily
0P6S Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€18.41 - €36.08
Previous Close€18.95
Volume1.80M
Average Volume (3M)672.03K
Market Cap
€18.60B
Enterprise Value€49.92B
Total Cash (Recent Filing)€10.15B
Total Debt (Recent Filing)€41.32B
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 05, 2025EPS Estimate
€0.98Last Dividend Ex-Date
Apr 29, 2024Dividend Yield0.58%
Share Statistics
EPS (TTM)-0.90
Shares OutstandingN/A
10 Day Avg. Volume24,185
30 Day Avg. Volume672,028
Standard Deviation0.05
R-Squared0.10
Alpha0.00016
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1.16
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.13Price Target Upside37.90% Upside
Rating ConsensusHold
Number of Analyst Covering15
Bayer News
Bulls Say, Bears Say
Bulls Say
Consumer HealthConsumer Health delivers on growth and margins: Q3 showed healthy organic growth of 6%, predominantly driven by +5% in prices.
Financial PerformanceBayer stock is seen to offer substantial upside in the medium term, with a SOTP value of approximately €60 per share.
PharmaceuticalsPharma is expected at the high end of the range in terms of sales and margin.
Bears Say
Financial OutlookThe company's earnings prospects for 2025 were disappointing, and the share price reacted negatively.
Operational ChallengesThe cautious tone for 2025 is a concern for investors, as operating cash flow should be used to repay company debt, while there is still uncertainty on the glyphosate litigation costs.
Sales PerformanceThe generic headwind at Xarelto intensified, leading to forecasted sales losses of €1bn in 2025 and another €800m in 2026.
---
Options Prices
Currently, No data available
---
Ownership Overview
― Insiders
11.54% Mutual Funds
<0.01% Other Institutional Investors
76.46% Public Companies and
Individual Investors
0P6S FAQ
What was Bayer’s price range in the past 12 months?
Bayer lowest share price was €18.41 and its highest was €36.08 in the past 12 months.
What is Bayer’s market cap?
Currently, no data Available
When is Bayer’s upcoming earnings report date?
Bayer’s upcoming earnings report date is Mar 05, 2025 which is in 73 days.
How were Bayer’s earnings last quarter?
Bayer released its earnings results on Nov 12, 2024. The company reported €0.24 earnings per share for the quarter, missing the consensus estimate of €0.314 by -€0.074.
Is Bayer overvalued?
According to Wall Street analysts Bayer’s price is currently Undervalued.
Does Bayer pay dividends?
Bayer pays a Annually dividend of €0.109 which represents an annual dividend yield of 0.58%. See more information on Bayer dividends here
What is Bayer’s EPS estimate?
Bayer’s EPS estimate is €0.98.
How many shares outstanding does Bayer have?
Bayer has 982,424,100 shares outstanding.
What happened to Bayer’s price movement after its last earnings report?
Bayer reported an EPS of €0.24 in its last earnings report, missing expectations of €0.314. Following the earnings report the stock price went down -12.229%.
Which hedge fund is a major shareholder of Bayer?
Currently, no hedge funds are holding shares in GB:0P6S
---
Bayer Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€26.13 (37.90% Upside)
€26.13 (37.90% Upside)
Insider Transactions
Bought Shares
Worth €234.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.57%
12-Months-Change
Fundamentals
Return on Equity
-2.75%
Trailing 12-Months
Asset Growth
-8.78%
Trailing 12-Months
Company Description
Bayer
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides just over half of the company's sales and includes pharmaceutical drugs as well as vitamins. The company has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.
---
0P6S Stock 12 Month Forecast
Average Price Target
€26.13
▲(37.90% Upside)
Technical Analysis
Best Analysts Covering 0P6S
1 Year
1 Year Success Rate
8/28 ratings generated profit
1 Year Average Return
-14.84%
reiterated a buy rating 26 days ago
Copying Peter Spengler's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -14.84% per trade.
---